X

Clarkson receives $400,000 to study technology for real-time monitoring of neurotransmitters

Posted 1/23/12

POTSDAM – Clarkson University has received $440,000 from the National Institute of Neurological Disorders and Stroke for a team led by Chemical & Biomolecular Science Professor Dr. Silvana …

This item is available in full to subscribers.

Please log in to continue

Log in

Clarkson receives $400,000 to study technology for real-time monitoring of neurotransmitters

Posted

POTSDAM – Clarkson University has received $440,000 from the National Institute of Neurological Disorders and Stroke for a team led by Chemical & Biomolecular Science Professor Dr. Silvana Andreescu, according to Congressman Bill Owens.

The team is developing a novel sensing technology for real-time monitoring of neurotransmitters. The technology will be used to study neurophysiological events in collaboration with neurophysiologists and medical doctors at Dartmouth Medical School.

The project is a collaborative effort between Dr. Andreescu at Clarkson and Dr. James C. Leiter at Dartmouth.

“This is great news for Clarkson as well as the Village of Potsdam,” Owens said. “This funding will allow Clarkson to continue the tremendous work for which the facility is known, and give us a greater understanding of diseases and the cures that prevent them. I would like to thank Dr. Silvana Andreescu and the rest of her department for their hard work in this field, as well as President Collins for the leadership and guidance he provides our community.”

The funding will allow Dr. Andreescu and her team to develop a novel sensing technology for real-time monitoring of the chemical substances (like lactate and glutamate) associated with neural signaling and function during oxygen deprivation in the brain. The technology will provide real-time assessment of the changes in these neurological factors and provide answers to fundamental questions related to the biochemical and cellular events involved in conditions of oxygen deprivation.

Said Clarkson Pres. Tony Collin, “The NIH funding for Dr. Andreescu’s research emphasizes Clarkson’s leading role in research that can bring new disease prevention and management solutions to the market.”

Said Andreescu, “These studies have relevance for human health because tissue oxygen levels vary in many diseases, and the role of the mediators of injuries (like lactate and glutamate) in oxygen-deprived conditions is not well understood.”

Studies of the mechanisms of injury during hypoxia (deprivation of oxygen) and ischemia (lack of blood) faced major technical limitations in the past. It has been difficult to measure the mediators of brain injury because either the sensors for these mediators do not exist or they do not function well in low-oxygen environments in live tissue. For these reasons, it has also been difficult to analyze in real-time the evolution of ischemic and hypoxic brain injuries and the evolution of repair to the brain.

The Clarkson researchers are developing novel electrochemical biosensors for the neurotransmitters glutamate and lactate that will remain effective even in a low-oxygen environment. The new sensor design will expand the arsenal of accessible probes for real-time measurement of glutamate and lactate and provide new methods for studying the neurobiology of these neurotransmitters in hypoxic conditions.

This research will facilitate study and further fundamental understanding of glutamate and lactate neurotransmission in a variety of other neurological disorders in which oxygen is restricted.

Dr. Andreescu received a joint Ph.D. in chemistry from the University of Perpignan, France, and University of Bucharest, Romania. She completed a postdoctoral fellowship in analytical chemistry at SUNY Binghamton. Her research interests include microencapsulation techniques, bioremediation and biosensors.